drugset / Trial / NCT03045770
mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study was to compare the efficacy and safety of mFOLFOX, mFOLFIRI and FOLFPTX as first-line treatment in AGC or EGJA.
Timeline
- Start
- 2017-02-10
- Primary completion
- 2019-12-30
- Completion
- 2019-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 95 mg/m2 | — |
| Background | Levoleucovorin | Unknown | 200 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | — |